BioLASCO Taiwan Co., Ltd. (6662) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for BioLASCO Taiwan Co., Ltd. (6662:TWSE), powered by AI.

Current Price
$29.95
Sector
Healthcare
What is the BioLASCO Taiwan Co., Ltd. stock price forecast?

BioLASCO Taiwan Co., Ltd. is currently trading at $29.95. View real-time AI analysis on Alpha Lenz.

What is BioLASCO Taiwan Co., Ltd. insider trading activity?

View the latest insider trading data for BioLASCO Taiwan Co., Ltd. on Alpha Lenz.

What is BioLASCO Taiwan Co., Ltd.'s P/E ratio?

View BioLASCO Taiwan Co., Ltd.'s valuation metrics on Alpha Lenz.

BioLASCO Taiwan Co., Ltd.

TWSE · 6662
NT$29.95-0.25(-0.83%)
Ask about BioLASCO Taiwan Co., Ltd.'s future dividend policy...
Alpha Chat Insight

BioLASCO Taiwan Co., Ltd.'s ROE is 9.4%. Explore profitability and growth together.

Ask for details

Company Overview

BioLASCO Taiwan Co., Ltd. is a biotechnology firm specializing in the breeding, production, and supply of Specific Pathogen Free (SPF) laboratory animals, such as rats and mice, to support biomedical research and pharmaceutical development. The company's offerings encompass a comprehensive portfolio of outbreed stocks, inbred strains, immune-deficient models, and specialized animal models—critical tools for laboratories in Taiwan and internationally. Beyond laboratory animals, BioLASCO also provides a broad suite of laboratory equipment and support services, including diagnostic kits, endotoxin detection, animal facility systems, and research instrumentation tailored for preclinical studies. Notably, the company partners with leading international organizations and holds full accreditation from AAALAC International, reflecting its commitment to high standards in animal welfare and research quality. By enabling reliable and reproducible animal-based studies, BioLASCO plays a pivotal role in advancing life sciences and medical innovation across multiple sectors, from academic research to pharmaceutical enterprise, thus serving as a vital supplier within the global healthcare and biotechnology industry.

SectorHealthcare
IndustryBiotechnology
Employees91

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$262.66MRevenue
0.00Shares Out
91Employees

Margins

39.89%Gross
24.06%EBITDA
18.32%Operating
18.87%Pre-Tax
16.15%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

3.65%Rev 3Yr
-2.55%Rev 5Yr
-0.79%Op Inc 3Yr
-9.11%Op Inc 5Yr
0.09%Net Inc 3Yr
-7.54%Net Inc 5Yr

Returns

7.04%ROA
9.35%ROE
8.56%ROIC

Financial Health

NT$80.71MCash & Cash Equivalents
NT$54.15MNet Debt
29.46%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

BioLASCO Taiwan Co., Ltd. (ticker: 6662) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 91 employees.

The current price is 29.95 with a P/E ratio of -x and P/B of -x.

ROE is 9.35% and operating margin is 18.32%. Annual revenue is $263M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
BioLASCO Taiwan Co., Ltd. (6662) Stock Forecast 2026 $29.95 — Price, Financials & Analyst Targets | Alpha Lenz